Completed OBSERVATIONAL NCT00902980

Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics

Regional Transplant Programs Study of Immunosuppressive Therapy Related Toxicities in Renal Transplant Recipients Managed at Regional or Satellite Community Nephrology Clinics

Sponsor: Astellas Pharma Canada, Inc.

Conditions Kidney Transplantation

Interventions Chart Review

Updated 7 times since 2017 Last updated: Sep 17, 2014 Started: Apr 30, 2005 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Kidney Transplantation, this trial is completed. The trial is conducted by Astellas Pharma Canada, Inc. and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Canada, Inc.
Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Greater Sudbury, Canada , Halifax, Canada , London, Canada , Mississauga, Canada , Moncton, Canada , New Westminster, Canada , Saint John, Canada , Sault Ste. Marie, Canada , Sydney, Canada , Thunder Bay, Canada and 2 more locations